Skip to content
value.today
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2017
Total raised
$128 M
2 rounds on record
Latest round
$72 M
Dec 2020
First round on record
Aug 2019
Today
Went public
See the company page

Werewolf Therapeutics, Inc. is listed today as Werewolf Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Werewolf Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$72 MNo. 2$50 to $250 million

Werewolf Therapeutics, Inc.: Raise no. 2, Dec 2020

Investors in this round

19 investors had bought by the notice of Jan 7, 2021: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 26 investors are named for Werewolf Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$72 M of $72 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Hicklin · Executive Officer, Director
  • David Cordo · Executive Officer
  • Alon Lazarus · Director
  • Briggs Morrison · Director
  • Derek DiRocco · Director
  • Elise Wang · Director
  • Luke Evnin · Director
  • Sakae Asanuma · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Hicklin, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 7, 2021. Read the notice at the SEC.

equitySEC
Aug 2019$56 MNo. 1$50 to $250 million

Werewolf Therapeutics, Inc.: Raise no. 1, Aug 2019

Investors in this round

10 investors had bought by the notice of Aug 13, 2020: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 26 investors are named for Werewolf Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Hicklin · Executive Officer, Director
  • David Cordo · Executive Officer
  • Alon Lazarus · Director
  • Briggs Morrison · Director
  • Christoph Westphal · Director
  • Luke Evnin · Director
  • Sakae Asanuma · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Hicklin, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 13, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Werewolf Therapeutics, Inc., its revenue in fiscal 2024 came from these business segments: Reportable $1.88 million.

    Annual report (SEC XBRL) · Dec 2024

  • Werewolf Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2021

Products and services#

No products or services of Werewolf Therapeutics, Inc. are on record.

Investors#

26 named in official filings. Open an investor to see everything it has backed.

Investors in Werewolf Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Arkin Bio Ventures 2 L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Arkin Bio Ventures GPGP Ltd.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Deerfield Partners, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
HBM Healthcare Investments (Cayman) Ltd.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Longwood Fund III GP, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Longwood Fund III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM Asset Management Investors BV2014 LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM Bioimpact LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM BioVentures 2014 (B), L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM BioVentures 2014 GP LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM BioVentures 2014 LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM BioVentures 2014, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM Oncology Impact Management GP LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM Oncology Innovations Fund GP LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
MPM Oncology Innovations Fund LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Oncology Impact Fund (Cayman) Management L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Sphera Funds Management LTD.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sphera Global Healthcare GP Ltd.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sphera Global Healthcare Management LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Taiho Ventures LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
UBS Oncology Impact Fund L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
UpmcPersonnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.

Largest shareholders today

Institutions holding Werewolf Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Werewolf Therapeutics, Inc.
NameRoleNamed in
Daniel HicklinExecutive officerJan 2021
David CordoExecutive officerJan 2021
Alon LazarusDirectorJan 2021
Briggs MorrisonDirectorJan 2021
Daniel HicklinDirectorJan 2021
Derek DiRoccoDirectorJan 2021
Elise WangDirectorJan 2021
Luke EvninDirectorJan 2021
Sakae AsanumaDirectorJan 2021
Christoph WestphalDirectorAug 2020
Patrick BaeuerleDirectorAug 2019

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.